Cost-effectiveness of Helicobacter pylori eradication in India: To live and let live ... expensively?

Indian Journal of Gastroenterology

Volumn 16, Issue SUPPL. 1, 1997, Pages

  Bhatia, S J ^a   Kulkarni, S G ^a  

^a BYL NAIR CHARITABLE HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; CIMETIDINE; CLARITHROMYCIN; FAMOTIDINE; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NORFLOXACIN; OMEPRAZOLE; PEFLOXACIN; PROTON PUMP INHIBITOR; RANITIDINE; SECNIDAZOLE; SUCRALFATE; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; COST EFFECTIVENESS ANALYSIS; DUODENUM ULCER; DYSPEPSIA; HEALTH CARE COST; HELICOBACTER PYLORI; HUMAN; INDIA; MAJOR CLINICAL STUDY; NONHUMAN; RECURRENT DISEASE; TREATMENT OUTCOME; ULCER HEALING;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; DUODENAL ULCER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTAMINE H2 ANTAGONISTS; HUMANS;

EID: 0031418624     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)